Palvella Therapeutics (PVLA) Interest Expenses (2013 - 2026)
Palvella Therapeutics (PVLA) posted quarterly Interest Expenses of $314.3 million for Q1 2026, up 714.25% year-over-year from $38.6 million in Q1 2025, and up 714.25% quarter-over-quarter from $38.6 million in Q1 2025.
Palvella Therapeutics (PVLA) Interest Expenses (2013 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Interest Expenses for 14 consecutive years, with $314.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 714.25% year-over-year to $314.3 million; the TTM figure through Mar 2026 stood at $314.3 million (up 714.25% YoY), while the FY2025 annual figure was $131.2 million, up 40.62% from the prior year.
- Interest Expenses improved to $314.3 million in Q1 2026 per PVLA's latest filing, from $38.6 million in the prior quarter.
- Across five years, Interest Expenses topped out at $314.3 million in Q1 2026 and bottomed at -$1.6 million in Q4 2023.
- Historically, Interest Expenses has averaged $27.4 million across 5 years, with a median of $500000.0 in 2022.
- Annual changes were most pronounced in 2023 — Interest Expenses plunged 300.0% — and 2026, when it surged 714.25%.
- Palvella Therapeutics' Interest Expenses stood at $800000.0 in 2022, then slumped by 300.0% to -$1.6 million in 2023, then jumped by 111.31% to $181000.0 in 2024, then surged by 21225.97% to $38.6 million in 2025, then soared by 714.25% to $314.3 million in 2026.
- Business Quant data shows PVLA's Interest Expenses at $314.3 million in Q1 2026, $38.6 million in Q1 2025, and $181000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Palvella Therapeutics | 2.25 Bn | 1.93 Bn | - | 396.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 396.80 Mn |
| Jun 30, 2026 | 396.80 Mn |
| Mar 31, 2026 | 314.30 Mn |
| Mar 31, 2026 | 314.30 Mn |
| Mar 31, 2025 | 38.60 Mn |
| Mar 31, 2025 | 38.60 Mn |
| Dec 31, 2024 | 181,000.00 |
| Dec 31, 2024 | 181,000.00 |
| Sep 30, 2024 | 220,000.00 |
| Sep 30, 2024 | 220,000.00 |
| Jun 30, 2024 | 29,000.00 |
| Jun 30, 2024 | 29,000.00 |
| Dec 31, 2023 | -1.60 Mn |
| Dec 31, 2023 | -1.60 Mn |
| Sep 30, 2023 | 500,000.00 |
| Sep 30, 2023 | 500,000.00 |
| Jun 30, 2023 | 500,000.00 |
| Jun 30, 2023 | 500,000.00 |
| Mar 31, 2023 | 500,000.00 |
| Mar 31, 2023 | 500,000.00 |